The S&P 500 has climbed for three consecutive calendar years and reached record levels in 2026, yet volatility has returned with force in recent months.
Investors are grappling with ongoing turmoil in Iran, elevated oil prices, rising inflation in the United States, and surging spending in the artificial intelligence space.
These pressures have weighed on the broader market periodically and could potentially trigger longer-lasting declines if conditions worsen further.
Dividend stocks present a compelling solution, offering shareholders recurrent passive income regardless of how the broader market performs at any given time.
Healthcare dividend payers are particularly attractive during uncertain periods, since the sector generates steady revenue even when the broader economy faces headwinds.
A strong starting point for dividend seekers is the list of Dividend Kings, companies that have raised their dividend payments for at least 50 consecutive years without interruption.
Johnson & Johnson (NYSE: JNJ) is one such company, having transformed its business after exiting consumer health products and concentrating fully on its pharmaceutical and medtech divisions.
J&J now boasts 28 products and platforms each generating more than $1 billion in annual revenue, with eight pharma brands growing at double-digit rates in the most recent quarter.
The healthcare giant is targeting more than $100 billion in total revenue this year, which would represent the highest revenue level in the company’s history.
J&J pays $5.36 per share in dividends, translating to a dividend yield of 1.9%, rewarding investors with consistent passive income alongside a high-performing healthcare business.
AbbVie (NYSE: ABBV) is the second Dividend King worth highlighting, best known for creating the world’s first $20 billion drug, immunology blockbuster Humira.
Humira has since lost exclusivity and experienced sales declines, but AbbVie navigated that transition by advancing newer immunology products Skyrizi and Rinvoq into dominant market positions.
In the most recent quarter, Skyrizi delivered revenue growth of approximately 24% to more than $5 billion, while Rinvoq grew at a similar pace to exceed $2 billion.
AbbVie also holds a leading aesthetics portfolio featuring anti-wrinkle treatment Botox and filler Juvederm, along with growing neuroscience and oncology divisions.
The company’s neuroscience segment showed particular strength, with bipolar disorder treatment Vraylar generating more than $1 billion in revenue alongside double-digit growth from several other drugs.
Total worldwide revenue advanced 10% to more than $16 billion in the latest quarter, demonstrating that AbbVie’s portfolio has more than compensated for the loss of Humira exclusivity.
AbbVie currently pays $6.92 per share in dividends, yielding 2.7% and cementing its reputation as a shareholder-friendly company committed to sustained dividend growth.
Both JNJ and ABBV carry long track records of raising dividend payments year after year, making them dependable anchors for any portfolio facing uncertain market conditions.
For investors looking to protect their portfolios while generating passive income, these two Dividend Kings represent a time-tested strategy that has endured decades of market disruption.
